Bio-Rad Laboratories (NYSE:BIO) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Bio-Rad Laboratories (NYSE:BIO) from a buy rating to a hold rating in a report released on Saturday.

A number of other equities research analysts have also recently issued reports on BIO. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, Citigroup lifted their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $256.87 on Friday. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $343.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.44 and a quick ratio of 3.94. The stock’s fifty day moving average price is $305.47 and its two-hundred day moving average price is $301.16. The firm has a market cap of $6.93 billion, a PE ratio of 9.20 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). The firm had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.95% and a net margin of 29.42%.The company’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business posted $2.90 EPS. On average, equities research analysts forecast that Bio-Rad Laboratories will post 10.81 EPS for the current year.

Institutional Trading of Bio-Rad Laboratories

Large investors have recently modified their holdings of the business. Quent Capital LLC bought a new position in shares of Bio-Rad Laboratories in the 3rd quarter worth $25,000. Danske Bank A S purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $30,000. Farther Finance Advisors LLC lifted its holdings in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after buying an additional 36 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 109 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its position in Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the period. Institutional investors own 65.24% of the company’s stock.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Management outlined a 2026 program to expand margins via operational improvements and cost actions, which could improve profitability over time. Bio?Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance
• Positive Sentiment: Management reiterated a focus on operational fixes and provided a slide deck and detailed Q&A on the call — useful for modeling forward margin improvement timing and one?time items. Q4 results presentation
• Neutral Sentiment: FY?2026 revenue guidance is modest: management expects roughly flat to low?single?digit top?line growth (about 0.5%–1.5%) with a revenue target around ~$2.6B — implies conservative near?term growth expectations. Bio?Rad Reports Fourth?Quarter and Full?Year 2025 Financial Results
• Neutral Sentiment: The company provided a full earnings call transcript and presentation that disclose drivers of the quarter and planned cost actions; these documents are important for forecasting the timing and magnitude of margin recovery. Earnings call transcript
• Negative Sentiment: Q4 EPS missed consensus: $2.51 actual vs. $2.57 expected, and revenue of $693.2M narrowly missed estimates — EPS declined from $2.90 a year ago, signaling pressure on short?term earnings momentum. Q4 earnings miss
• Negative Sentiment: The company reported a negative net margin (reported -26.4%), which likely reflects discrete charges or restructuring that compressed reported profitability and increased investor uncertainty. Market summary and ratios
• Negative Sentiment: Market reaction was sharp: shares dropped with elevated volume after the print and guidance; the combination of an earnings miss and conservative/ muted revenue growth guidance likely triggered the sell?off. Shares tumble after Q4 miss

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.